Back to Authors

Borroni, Barbara

https://orcid.org/0000-0001-9340-9814

A5090580473 | I4210114614

Mayo Clinic

Centro San Giovanni di Dio Fatebenefratelli

Citations 14

A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers

Brain | August 31, 2018 | Volume: 141 | Issue: 10 | Pages: 2895-2907

10.1093/brain/awy238 | PMID 30252044

Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers

Annals of Clinical and Translational Neurology | April 10, 2018 | Volume: 5 | Issue: 5 | Pages: 583-597

10.1002/acn3.559 | PMID 29761121

AbstractObjectiveTo evaluate poly(GP), a dipeptide repeat protein, and neurofilament light chain (NfL) as biomarkers in presymptomatic C9orf72 repeat expansion carriers and patients with C9orf72‐associated frontotemporal dementia. Additionally, to investigate the relationship of poly(GP) with indicators of neurodegeneration as measured by NfL and grey matter volume.MethodsWe measured poly(GP) and NfL levels in cerebrospinal fluid (CSF) from 25 presymptomatic C9orf72 expansion carriers, 64 symptomatic expansion carriers with dementia, and 12 noncarriers. We explored associations with grey matter volumes using region of interest and voxel‐wise analyses.ResultsPoly(GP) was present in C9orf72 expansion carriers and absent in noncarriers (specificity 100%, sensitivity 97%). Presymptomatic carriers had lower poly(GP) levels than symptomatic carriers. NfL levels were higher in symptomatic carriers than in presymptomatic carriers and healthy noncarriers. NfL was highest in patients with concomitant motor neuron disease, and correlated with disease severity and survival. Associations between poly(GP) levels and small grey matter regions emerged but did not survive multiple comparison correction, while higher NfL levels were associated with atrophy in frontotemporoparietal cortices and the thalamus.InterpretationThis study of C9orf72 expansion carriers reveals that: (1) poly(GP) levels discriminate presymptomatic and symptomatic expansion carriers from noncarriers, but are not associated with indicators of neurodegeneration; and (2) NfL levels are associated with grey matter atrophy, disease severity, and shorter survival. Together, poly(GP) and NfL show promise as complementary biomarkers for clinical trials for C9orf72‐associated frontotemporal dementia, with poly(GP) as a potential marker for target engagement and NfL as a marker of disease activity and progression.
[P4–189]: SYMPTOM ONSET IN GENETIC FRONTOTEMPORAL DEMENTIA

Alzheimer's & Dementia | October 20, 2017 | Volume: 13 | Issue: 7S_Part_28 | Pages: No page available

10.1016/j.jalz.2017.06.2056

[O4–02–02]: POLY‐GP DIPEPTIDE REPEATS AND NEUROFILAMENT LIGHT CHAIN AS BIOMARKERS IN PRESYMPTOMATIC AND SYMPTOMATIC FRONTOTEMPORAL DEMENTIA CAUSED BY C9ORF72 REPEAT EXPANSIONS

Alzheimer's & Dementia | October 20, 2017 | Volume: 13 | Issue: 7S_Part_25 | Pages: No page available

10.1016/j.jalz.2017.07.425